Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 21, 2018
April 23, 2020
49677313-1014-4cd6-be89-f28a08eb3f96
Related Documents
Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
Guidance DocumentMarch 21, 2024Center for Drug Evaluation and Research
Considerations for Complying with 21 CFR 211110
Guidance DocumentJanuary 6, 2025Center for Drug Evaluation and Research
Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment
Guidance DocumentFebruary 24, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox